Company intelligence / Profile preview

Neuravi

Galway, County Galway, Irelandjnjmedtech.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Neuravi’s EmboTrap Revascularization Device demonstrated restoration of significant blood flow in 86% of treated patients with most regaining independent function. The device was CE-marked and commercialized in Europe; pivotal trials were ongoing/preparing for US approval at the time of acquisition.

Therapeutic areas: Cardiovascular
Modalities: DeviceMedical device for neurointerventional therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

EmboTrap

Commercial

Indications: Acute ischemic stroke

Partnerships

Collaborations via NTI with clinicians/researchers; no major pharma

Beyond the preview

Go deeper on Neuravi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuravi.

Explore the full profile